Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Depreciation & Amortization (CF): 2012-2024

Historic Depreciation & Amortization (CF) for Rocket Pharmaceuticals (RCKT) over the last 11 years, with Dec 2024 value amounting to $7.2 million.

  • Rocket Pharmaceuticals' Depreciation & Amortization (CF) rose 45.98% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.0 million, marking a year-over-year increase of 32.67%. This contributed to the annual value of $7.2 million for FY2024, which is 46.06% up from last year.
  • Per Rocket Pharmaceuticals' latest filing, its Depreciation & Amortization (CF) stood at $7.2 million for FY2024, which was up 46.06% from $4.9 million recorded in FY2023.
  • In the past 5 years, Rocket Pharmaceuticals' Depreciation & Amortization (CF) registered a high of $7.2 million during FY2024, and its lowest value of $1.1 million during FY2020.
  • Over the past 3 years, Rocket Pharmaceuticals' median Depreciation & Amortization (CF) value was $4.9 million (recorded in 2023), while the average stood at $5.4 million.
  • Data for Rocket Pharmaceuticals' Depreciation & Amortization (CF) shows a peak YoY soared of 182.97% (in 2021) over the last 5 years.
  • Over the past 5 years, Rocket Pharmaceuticals' Depreciation & Amortization (CF) (Yearly) stood at $1.1 million in 2020, then spiked by 182.97% to $3.2 million in 2021, then rose by 21.36% to $3.9 million in 2022, then climbed by 25.74% to $4.9 million in 2023, then soared by 46.06% to $7.2 million in 2024.